Acoustiic closes funding round, expands its team and facilities

Paul Reynolds, Co-founder and Chief Technology Officer at Acoustiic

Acoustiic, Inc., a healthcare firm at the forefront of next-generation therapeutic ultrasound systems, announced closing a funding round and expanding its team and facilities to develop non-invasive, early treatment of multiple diseases. The firm is creating an ultrasound tech platform for the treatment of a wide variety of potential clinical indications in a compact, modular, and versatile system to further improve patient outcomes and lowering costs.

What is the market offering of Acoustiic?

For treatment of one of the indications, liver and pancreatic cancer, Acoustiic has received Breakthrough Device Designation from the United States Food and Drug Administration. The funding will accelerate the company’s production of its first-generation therapy system, while continuing development of next-generation systems for wider indication application.

Acoustiic’s new 7,500 square foot office and manufacturing facility for development, testing, and production allows for ongoing future expansion. The organisation has expanded its global team of the world’s leading experts in medical device manufacture and delivery.

What were the executives’ thoughts on the funding?

“We are extremely excited to be a step closer to delivering a quantum leap in non-invasive healthcare to patients in desperate need. This funding ensures we have the facilities, equipment, staff, and runway to deliver innovative medical technology and gives us support through the regulatory process,” said Sean Taffler, Ph.D., CEO and Cofounder of Acoustiic.

“The use of non-invasive treatment techniques will be a game changer for hospitals and patients alike, bringing sci-fi style healthcare into the mainstream. We’re bringing together leading technologies in a way that is currently unavailable commercially, and that sets the basis for a platform technology to expand advanced healthcare for the next decade,” commented Paul Reynolds, Ph.D, Co-founder and Chief Technology Officer of Acoustiic.

“Acoustiic’s platform will revolutionize medical care globally. While we have advanced care for diseases like cancer, the surgery, chemotherapy, and radiation take a high toll on patients and come at a high cost to the healthcare system,” said Anil Sethi, Cofounder of Acoustiic.

“Acoustiic’s technology aims to make many surgeries non-invasive and reduce or even eliminate the need for chemo and radiation that cause major systemic issues,” Sethi said.